NICE recommends against Avastin, Nexavar, Sutent and Torisel for Kidney Cancer « Kinase News

Blogroll
Tags
AstraZeneca aurora Avastin bayer Bcr-Abl bevacizumab BMS c-kit cetuximab EGFR ErbB-2 ErbB2 erbitux Exelixis Genentech GlaxoSmithKline Gleevec GSK HER1 HER2 IGF-1R Imatinib ImClone JAK2 kinase Merck-Serono Met mTOR multikinase Nexavar Novartis onyx PDGF Pfizer phase I Phase II phase iii PI3K Preclinical regulatory Research Roche sorafenib VEGF VEGFR2
Providing a resource for information on kinase inhibitors

NICE recommends against Avastin, Nexavar, Sutent and Torisel for Kidney Cancer

Posted on August 8, 2008 by crimsoncanary

The UK’s National Institute for Health and Clinical Excellence (NICE) has made a preliminary ruling stating that Avastin, Nexavar, Sutent and Torisel are not effective enough to warrant their high cost and shouldn’t be prescribed to new patients in Britain.

Filed under: Kinase receptor, kinase | Tagged: Avastin, bayer, bevacizumab, Genentech, kinase, mTOR, multikinase, Nexavar, onyx, Pfizer, regulatory, Roche, sorafenib, SU-11248, SU11248, sunitinib, sutent, temsirolimus, torisel, VEGF, Wyeth

« FDA grants SuperGen Orphan Drug Designation for MP-470 in Glioblastoma Multiforme Carna bioscience partner with Caliper for kinase profiling and assays »